Exenatide + rosiglitazone added to metformin

July 2010
Internal Medicine Alert;7/29/2010 Supplement, p112
The article reports that initial therapy for type 2 diabetes (DM2) should be mixed with metformin with the add-on therapy of exenatide (EXE) and rosiglitazone (ROS) which are effective therapies for glucose control.


Related Articles

  • New England Journal of Medicine: 2 drugs better than 1 to treat youth with type 2 diabetes.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article discusses a study funded by the U.S. National Institutes of Health which showed that a combination of two diabetes drugs including metformin and rosiglitazone was more effective in treating youth with recent-onset type 2 diabetes than metformin alone.

  • Combination therapy to prevent DM2.  // Internal Medicine Alert;9/29/2010 Clinical Briefs, p144 

    The article offers a news brief on the study of combined dose of low-dose metformin (500 mg bid) and low-dose rosiglitazone (2 mg qd) or placebo for the prevention of type 2 diabetes.

  • Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin. Defronzo, Ralph A.; Triplitt, Curtis; Qu, Yongming; Lewis, Michelle S.; Maggs, David; Glass, Leonard C. // Diabetes Care;May2010, Vol. 33 Issue 5, p951 

    OBJECTIVE--Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on β-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS-- In this 20-week, randomized,...

  • TODAY � A Stark Glimpse of Tomorrow. Allen, David B. // New England Journal of Medicine;6/14/2012, Vol. 366 Issue 24, p2315 

    The article focuses on the study, Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY), on the efficacy of metformin, rosiglitazone and lifestyle-intervention in maintaining glycemic control in children and adolescents. Results show that 52% of participants administered with...

  • Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Booth, Gillian L. // Evidence Based Medicine;Jun2009, Vol. 14 Issue 3, p7 

    The article presents a randomised controlled trial which investigates the effectiveness of intensive and standard glucose control in controlling death to patients with type 2 diabetes. It notes that the study was conducted in 20 sites in the U.S. Result shows that oral metformin plus...

  • Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance. Home, Philip D // Evidence Based Medicine;Feb2011, Vol. 16 Issue 1, p10 

    A review is presented of the article "Low-Dose Combination Therapy With Rosiglitazone and Metformin to Prevent Type 2 Diabetes Mellitus (CANOE trial): A Double-Blind Randomised Controlled Study" by B. Zinman et al., which appeared in a 2010 issue of "The Lancet".

  • Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. Kahn, Steven E.; Lachin, John M.; Zinman, Bernard; Haffner, Steven M.; Aftring, R. Paul; Paul, Gitanjali; Kravitz, Barbara G.; Herman, William H.; Viberti, Giancarlo; Holman, Rury R. // Diabetes;May2011, Vol. 60 Issue 5, p1552 

    OBJECTIVE--ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell...

  • Combination of treatments 'can help prevent diabetes'.  // GP: General Practitioner;6/11/2010, p13 

    The article presents the findings of a research conducted on the effectiveness of combination therapy with rosiglitazone and metformin on patients with impaired glucose tolerance (IGT). The research reveals that the therapy half the maximum dose is highly effective in prevention of type-2...

  • Combo best for youths with type 2 diabetes.  // Clinical Advisor;Jul2012, Vol. 15 Issue 7, p21 

    The article reports that rosiglitazone (Avandia) in combination with metformin can help children and adolescents with new-onset type 2 diabetes; and that adding an intensive lifestyle intervention to metformin doesn't provides more benefits that metformin therapy alone.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics